TYK2 and prostate carcinoma: In colon cancer, GRPR enhances invasion through the RhoA/ROCK pathway [43], while in prostate cancer, GRPR overexpression promotes a malignant phenotype via activation of AKT1, PKCε, TYK2, and MST1 pathways [63].